Show simple item record

dc.contributor.authorLiposits, Gabor Isivan
dc.contributor.authorRyg, Jesper
dc.contributor.authorSkuladottir, Halla
dc.contributor.authorWinther, Stine B.
dc.contributor.authorMöller, Sören
dc.contributor.authorHofsli, Eva
dc.contributor.authorShah, Carl-Henrik
dc.contributor.authorPoulsen, Laurids Østergaard
dc.contributor.authorBerglund, Åke
dc.contributor.authorQvortrup, Camilla
dc.contributor.authorOsterlund, Pia
dc.contributor.authorGlimelius, Bengt
dc.contributor.authorSorbye, Halfdan
dc.contributor.authorPfeiffer, Per
dc.date.accessioned2023-03-03T12:28:02Z
dc.date.available2023-03-03T12:28:02Z
dc.date.created2022-12-24T12:45:23Z
dc.date.issued2022
dc.identifier.citationJournal of Geriatric Oncology. 2022, 14 (1), 1-9.en_US
dc.identifier.issn1879-4068
dc.identifier.urihttps://hdl.handle.net/11250/3055752
dc.description.abstractIntroduction - Appropriate patient selection based on functional status is crucial when considering older adults for palliative chemotherapy. This pre-planned analysis of the randomized NORDIC9-study explored the prognostic value of four functional status measures regarding progression-free survival (PFS) and overall survival (OS) in vulnerable older patients with metastatic colorectal cancer (mCRC) receiving first-line palliative chemotherapy. Materials and methods - Patients ≥70 years of age with mCRC not candidates for standard full-dose combination chemotherapy were randomized to receive full-dose S1 or reduced-dose S1 + oxaliplatin. At baseline, functional status was assessed using ECOG performance status (ECOG PS), frailty phenotype, Geriatric 8 (G8), and Vulnerable Elderly Survey-13 (VES-13). Multivariable regression models were applied and C-statistics were estimated. Results - In total, 160 patients with a median age of 78 years (IQR: 76–81) were included. While in univariate analyses, ECOG PS, frailty phenotype, and VES-13 were statistically significantly associated with differences in OS between subgroups, G8 was not (HR = 1.55, 95%CI: 0.99–2.41, p = 0.050). In multivariable analyses adjusted for age, sex, body mass index, and treatment allocation, we found significant differences between subgroups for all applied tools and with C-statistics in the moderate range for ECOG PS and VES-13. Concerning PFS, statistically significant differences were observed between subgroups of ECOG PS, G8, and VES-13 both in uni- and multivariable analyses, but not for frailty phenotype. Discussion - In this Nordic cohort of vulnerable older patients with mCRC, baseline ECOG PS, frailty phenotype, G8, and VES-13 showed prognostic value regarding overall survival, and moderate predictive value of models based on ECOG PS and VES-13 was demonstrated.en_US
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titlePrognostic value of baseline functional status measures and geriatric screening in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy – The randomized NORDIC9-studyen_US
dc.title.alternativePrognostic value of baseline functional status measures and geriatric screening in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy – The randomized NORDIC9-studyen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.source.pagenumber1-9en_US
dc.source.volume14en_US
dc.source.journalJournal of Geriatric Oncologyen_US
dc.source.issue1en_US
dc.identifier.doi10.1016/j.jgo.2022.11.007
dc.identifier.cristin2097330
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Navngivelse 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse 4.0 Internasjonal